Stocks to Watch: Nvidia Partners with SK Hynix, Marvell and Flex Join S&P 500
Several companies are experiencing notable stock movements due to partnerships and index changes, which could influence investor sentiment and market dynamics.
Ticker: RHHBY
Roche
Pharma
Healthcare
Drug Manufacturers - General
Price
54.70
Reco
Buy
Potential
65
Risk
44
Updated
2026-07-25
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
Description
Company and Business Model
Roche is a global healthcare company specializing in pharmaceuticals and diagnostics. Its core products include prescription medications, particularly in oncology, immunology, and neuroscience, as well as diagnostic tools for various diseases. Major business segments are Pharmaceuticals and Diagnostics, with primary revenue sources stemming from drug sales and diagnostic testing services. The company is known for its strong research and development capabilities, contributing to its innovative product pipeline.
Investment Profile
Roche's investment profile is characterized by a balanced approach, appealing to investors seeking both growth and dividends. The company offers a stable dividend yield, making it attractive for income-focused investors, while its strong revenue growth indicates potential for capital appreciation. This combination positions Roche as suitable for those looking for a reliable investment with moderate risk.
Category: Pharma
Sector: Healthcare
Industry: Drug Manufacturers - General
Investment style: Growth
Horizon: Long-term
Company type: Blue Chip
Company type: Market Leader
Fundamental metrics (experimental) Updated: 2026-07-26
- EPS (TTM) — earnings per share for the last 12 months, $
- 2.84
- Revenue QoQ — quarter-over-quarter revenue growth
- 2.3%
- EPS surprise
- 5.1%
- 20d volatility
- 1.9%
- Dividend yield
- 2.8%
- last ex-date
- 2026-03-13
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-25 | Hold | Buy | Strong revenue growth and solid dividend yield. |
| 2026-07-07 | Buy | Hold | Stable dividend, but mixed momentum signals present risks. |
| 2026-06-25 | Sell | Buy | Stable dividend, moderate growth, uncertain market conditions. |
| 2026-06-19 | Buy | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-06-05 | Sell | Buy | Strong revenue growth, but mixed momentum signals. |
| 2026-06-03 | Hold | Sell | Weak momentum and high risk limit upside potential. |
| 2026-06-01 | Buy | Hold | Solid fundamentals, but mixed momentum signals present uncertainty. |
| 2026-05-22 | Hold | Buy | Stable dividend, but recent volatility raises concerns. |
| 2026-05-08 | — | Hold | Stable dividends, but mixed momentum and performance. |
| 2026-05-08 | Buy | Buy | Компания Roche демонстрирует стабильный рост выручки и дивидендную доходность, однако недавние колебания цен и снижение на коротких сроках могут указывать на неопределенность. Рекомендуется удерживать акции до более ясно |
| 2026-04-24 | — | Buy | Компания Roche демонстрирует сильный рост выручки и положительную динамику акций за последние 120 дней. Дивидендная доходность также привлекательна, что делает её хорошим объектом для инвестиций. |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2025-12-10 | HSBC | Target Raised | 50 → 57 | 48.66 |
| 2025-10-02 | HSBC | Rating Upgraded | — → 50 | 44.83 |
News Page 1 of 1